Iovance Biotherapeutics Inc（IOVA）股票分析

$14.090

-0.049 (-0.35%)收盘时

Loading chart…

最高: 14.300
开盘: 14.185
成交量加权均价: 13.98
成交量: 7.76M
市值: 2.24B
最低: 13.540
成交额: 108.46M
企业价值/息税折旧摊销前利润（TTM）: -23.90

Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.

www.iovance.com

AI 分析 of Iovance Biotherapeutics Inc (IOVA)

买入

Iovance Biotherapeutics Inc is a good buy right now due to its recent revenue guidance increase to $410-$420 million for 2026, reflecting a nearly 60% growth from the previous year. The stock has shown a remarkable year-to-date change of +459.13%, and the RSI is currently at 49.083, indicating a balanced momentum. However, the main risk lies in its negative earnings per share (EPS) forecast of -0.09 for the upcoming quarter, which could impact investor sentiment.

分析师评级（7）

-32.58% 下跌空间

买入

7 买入

0 持有

0 卖出

当前: 14.09

最低

1.50

平均

9.50

最高

17.00

Baird

中性

$11

2026-10-08

Baird

2026-10-08

目标价

$11

中性

Wells Fargo

增持

$18

2026-09-30

Wells Fargo

2026-09-30

目标价

$18

增持

H.C. Wainwright

买入

$20

2026-09-29

H.C. Wainwright

2026-09-29

目标价

$20

买入

Barclays

增持

$15

2026-09-17

Barclays

2026-09-17

目标价

$15

增持

TD Cowen

买入

$10

2026-08-25

TD Cowen

2026-08-25

目标价

$10

买入

查看全部评级

估值指标

Iovance Biotherapeutics Inc（IOVA）当前预期市盈率为 0.00，5 年平均预期市盈率为 -5.47。

预期市盈率

严重高估

5 年均值 P/E

-5.47

当前P/E

0.00

高估

-2.82

低估

-8.12

预期 EV/EBITDA

严重低估

5 年均值 EV/EBITDA

-5.06

当前EV/EBITDA

-23.90

高估

-1.01

低估

-9.11

预期市销率

合理

5 年均值 P/S

43.62

当前P/S

10.79

高估

171.45

低估

-84.21

Alphio AI 对 IOVA 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%IOVA

$5.72

情景价格

基

基准

基准 · 50%IOVA

$4.08

情景价格

悲

悲观

悲观 · 25%IOVA

$3.72

情景价格

持有 IOVA 的大户

Invenomic Capital Management LP

+ 持有IOVA

+5.23%

3个月收益率

事件时间线

2026-10-23 (ET)